On March 05, 2026 both William Blair and Raymond James maintained Outperform on Compass Therapeutics, Inc. (CMPX), marking a steady endorsement after the company’s Q4 results. The CMPX analyst rating appears unchanged by either firm, with Raymond James specifically citing the recent quarterly report. Investors should note small intraday declines of -1.34% and -1.52% reported alongside the reiterations and a market cap of $764,723,245

CMPX analyst rating actions on March 05, 2026

Both firms acted on March 05, 2026 and maintained Outperform for CMPX. William Blair reiterated Outperform at 11:37 AM and Raymond James reiterated Outperform at 11:18 AM following Q4 results. The StreetInsider posts reported small price moves of -1.34% (-$0.07) and -1.52% (-$0.08) respectively, with no price targets published in those notices

What the maintained Outperform ratings mean for investors

A maintained Outperform is an endorsement of relative upside versus peers rather than an upgrade. Investors should read these actions as analysts keeping conviction in Compass Therapeutics’ pipeline and execution. The lack of a new price target suggests analysts saw no need to revise valuation after Q4, and investors should focus on upcoming clinical milestones

Analyst notes, coverage context, and CMPX price target details

Raymond James tied its reiteration to Q4 results while William Blair issued a standalone reiteration; neither piece included a new CMPX price target. Full writeups are available on StreetInsider: Raymond James source and William Blair source

CMPX upgrade and CMPX downgrade history and analyst coverage

Recent action shows consistent positive coverage rather than upgrades or downgrades; the two March 05, 2026 entries are both maintained Outperforms. Historically, Compass Therapeutics has attracted coverage from mid‑cap biotech specialists and boutique research desks. The current record reflects continuity in sentiment, with no recent downgrades reported in these items

Stock reaction, market cap and short-term performance

The reiterations coincided with intraday declines of -1.34% and -1.52%, signaling short-term selling pressure despite unchanged analyst stances. Market capitalization stands at $764,723,245, and investors should monitor trading around clinical updates. Rating reiterations alone did not spark upward moves, underscoring the need for new catalysts

Meyka AI perspective and CMPX analyst rating grade

Meyka AI rates CMPX with a grade of B. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. As an AI-powered market analysis platform, Meyka AI tracks real-time analyst coverage and sees these maintained Outperforms as confirmation of existing analyst conviction rather than a directional signal

Final Thoughts

The March 05, 2026 analyst actions left the CMPX analyst rating steady with both William Blair and Raymond James maintaining Outperform. Neither firm published a new CMPX price target, and the market reacted with small intraday declines of -1.34% and -1.52%. For investors, maintained Outperforms mean analysts still prefer Compass Therapeutics versus peers, but they did not add new upside conviction. Key investor takeaways are to watch upcoming clinical readouts, balance sheet runway, and any future analyst notes that add or cut valuation assumptions. Meyka AI rates CMPX with a grade of B, reflecting relative strength versus benchmarks, sector performance, and existing analyst sentiment. These grades are not guarantees and we are not financial advisors; use them as one input in a wider research process and monitor primary filings and analyst reports for price target updates

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.